Drugs / Phenolic complex k110-42
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07284693 Comparator | Jan → Jul 2026 overdue | cognitive disorder | Mansoura University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Phenolic complex k110-42 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07284693 ↗ |
| Known as | Neumentix | “The phenolic complex K110-42 (Neumentix), derived from the extract of spearmint, has garnered attention for its potential benefits in cognitive performance.” NCT07284693 ↗ |
| Route | Oral | “900 mg/kg once oral in form of sachet for 6 month” NCT07284693 ↗ |